Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. BVAXF


Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

BioVaxys Technology Corp.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(328)
•••
Post by moneywagonon Oct 07, 2022 12:15pm
92 Views
Post# 35012464

BIOV 1 MILLION INCOMING & THE TRADE DAY IS SUPER YOUNG

BIOV 1 MILLION INCOMING & THE TRADE DAY IS SUPER YOUNG
C:BIOV - BioVaxys Technology Corp. - https://biovaxys.com
Sym-X Bid - Ask Last Chg %Ch Vol $Vol #Tr Open-Hi-Lo Year Hi-Lo Last Tr News Delay
BIOV - C   2.0 0.185 · 0.19 49.5 0.185 +0.01 5.7 908.1 138 161 0.17  0.19  0.145 0.465  0.085 11:56:22 Oct 06 15 min RT 2¢
CSE - C 2.0 0.185 · 0.19 49.5 0.185 +0.01 5.7 634.6 98 104 0.17  0.185  0.145 0.465  0.085 11:56:20   15 min
NEO ATS - U   0.19 +0.015 8.6 169.0 25 26 0.16  0.19  0.145   11:50:00   15 min
Omega - O   0.185 +0.01 5.7 43.5 7 11 0.15  0.185  0.15   11:56:22   15 min
Chi-X - X   0.155 -0.02 -11.4 37.0 5 7 0.145  0.155  0.145   10:37:56   15 min
CX2 - H   0.18 +0.005 2.9 22.5 4 3 0.155  0.18  0.15   11:46:48   15 min
TriAct - M   0.175     1.5   10            15 min

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities